Pursuant to the Employment Agreement, Dr. Gano will serve as Neurocrine Biosciences’ President and Chief Executive Officer effective October 11, 2024 (the “Effective Date”).
On October 7, 2024, Christopher Savoie resigned as President and Chief Executive Officer of the Company, as well as a member of the board of directors of the Company, in each case effective immediately.
The board of directors of the Company has appointed Sumit Kapur, the Company’s Chief Financial Officer, to serve as the Chief Executive Officer and principal executive officer, effective immediately.
Mr. Martucci will remain with the Company in a non-executive officer role.
Appointed
Xiaoyue Zhang
Chief Financial Officer
Wave Sync Corp.
Effective
2024-10-07
Filed
October 11, 2024, 7:59 PM ET
The Board also approved the appointment of Xiaoyue Zhang, a current member of the Board, as Chief Financial Officer (the “CFO”) of the Company, effective as of October 7, 2024.
Appointed
Hong Chen
Chief Executive Officer and Chairman of the Board
Wave Sync Corp.
Effective
2024-10-07
Filed
October 11, 2024, 7:59 PM ET
On October 7, 2024, the Board of Directors (the “Board”) approved the appointment of Hong Chen, a current member of the Board, as Chief Executive Officer (the “CEO”) and Chairman of the Board of the Company, effective as of October 7, 2024.
Departed
Hon Man Yun
Chief Executive Officer
Wave Sync Corp.
Effective
2023-10-03
Successor
Hong Chen
Filed
October 11, 2024, 7:59 PM ET
On October 3, 2023, Hon Man Yun passed away, thereby concluding his position as Chief Executive Officer of Wave Sync Corp.
Appointed
(interim)
Rakesh Prasad
Interim Chief Financial Officer (and principal financial and accounting officer)
On the same date, the Company appointed Rakesh Prasad, the Company’s Vice President of Finance, to serve as its Interim Chief Financial Officer (and principal financial and accounting officer), effective immediately, while the Company conducts its search for a new Chief Financial Officer.
Departed
William B. Miller
Chief Financial Officer (and principal financial and accounting officer)
On October 10, 2024, William B. Miller resigned from his position as Chief Financial Officer (and principal financial and accounting officer) of reAlpha Tech Corp. (the “Company”) and its subsidiaries, effective immediately.
On October 11, 2024, Lattice Semiconductor Corporation (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Tonya Stevens, the Company’s current Corporate Vice President and Corporate Controller, as Interim Chief Financial Officer in addition to her existing position at the Company, effective October 10, 2024.
Jonathan Javitt, Chairman of the Board of Directors of the Company, was appointed as Interim Chief Executive Officer concurrent with Mr. Willard’s resignation.
On October 7, 2024, Stephen Willard, the Chief Executive Officer of NRx Pharmaceuticals, Inc. (the “ Company ”) provided notice to the Board that he was resigning from the Company, effective immediately
Mark Lynch, a member of the Company’s Board of Directors, will serve as Interim Chief Financial Officer ("Interim CFO") effective as of November 4, 2024
Mark Matheos, Chief Financial Officer of Appian Corporation (the “Company”) notified the Company that he will be leaving the Company effective November 8, 2024, to pursue an opportunity as a CFO at another company.
the Board of Directors of the Company elected Taylor E. Luebke to succeed Mr. Lucian as Senior Vice President and Chief Financial Officer of the Company, effective January 1, 2025.
Robert G. Lucian, Senior Vice President and Chief Financial Officer, informed La-Z-Boy Incorporated (the “Company”) of his planned retirement from the Company at the end of the fiscal year, effective April 26, 2025.
On October 7, 2024, Mr. Stephen Kok Koon Tan resigned as CEO and director of Summit Networks Inc. (the “Company”).
Role change
(interim)
Barry Shin
Executive Vice President, Chief Operating Officer and Chief Financial Officer
TREVENA INC
Effective
2024-10-05
Filed
October 10, 2024, 7:59 PM ET
approved the termination of employment, without cause, of Carrie L. Bourdow, the Company’s President and Chief Executive Officer; Barry Shin, the Company’s Executive Vice President, Chief Operating Officer and Chief Financial Officer; and Mark A. Demitrack, MD, the Company’s Senior Vice President and Chief Medical Officer
Role change
(interim)
Carrie L. Bourdow
President and Chief Executive Officer
TREVENA INC
Effective
2024-10-05
Filed
October 10, 2024, 7:59 PM ET
approved the termination of employment, without cause, of Carrie L. Bourdow, the Company’s President and Chief Executive Officer; Barry Shin, the Company’s Executive Vice President, Chief Operating Officer and Chief Financial Officer; and Mark A. Demitrack, MD, the Company’s Senior Vice President and Chief Medical Officer
Departed
Wynne Comer
interim Chief Financial Officer
AGL Private Credit Income Fund
Effective
2024-10-08
Successor
Ted Gilpin
Filed
October 10, 2024, 7:59 PM ET
On October 8, 2024, Wynne Comer resigned from her position as the interim Chief Financial Officer of AGL Private Credit Income Fund (the “Company”), effective on such date.
Appointed
Ted Gilpin
Chief Financial Officer
AGL Private Credit Income Fund
Effective
2024-10-08
Filed
October 10, 2024, 7:59 PM ET
On October 8, 2024, the Board of Trustees (the “Board”) of Company appointed Ted Gilpin to serve as the Company’s Chief Financial Officer, effective on October 8, 2024.
Mr. Warren F. Kruger, Greystone's CEO, President, Chairman of the Board and a significant stockholder of Greystone, will assume the position of Chief Financial Officer (principal financial officer and principal accounting officer) until such time as a permanent candidate is employed.
Mr. R. Brice Dille has been relieved of his position as Interim Chief Financial Officer (principal financial officer and principal accounting officer) effective October 9, 2024.
On October 4, 2024, the Board of Directors (the “Board”) of bioAffinity technologies, Inc. (the “Company”) appointed J. Michael Edwards, who has served as the Company’s Interim Chief Financial Officer, as a consultant, since September 2024, to serve as Chief Financial Officer of the Company, effective November 5, 2024.
On October 8, 2024, ProMIS Neurosciences Inc. (the “Company”) appointed Neil Warma as the President and Chief Executive Officer (“CEO”) of the Company, effective August 1, 2024.
On October 4, 2024, Alexander Valdes, the Chief Financial Officer of T Stamp Inc., a Delaware corporation (the “Company”), submitted a notice of non-renewal of his employment agreement with the Company, providing a 90-day notice in accordance with the terms of his employment agreement, which was accepted by the Company.
Mr. Dwight Seegmiller, President and CEO of the Company and CEO of Hills Bank, will transition to a management advisory role effective January 1, 2025, through his retirement in April of 2025, to assist in the transition of leadership of the Company.
Kevin P. Riley, who, as the Company previously announced on June 14, 2024, will be departing as President and CEO in connection with his successor taking over those positions
pursuant to which Mr. Kim resigned from his positions as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective October 8, 2024
the Company appointed Christopher Degnan as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective on the Effective Date.
Michael A. Pedraja will be appointed as Executive Vice President, Finance and Chief Financial Officer (Designate) on or about February 3, 2025, and will then serve as Executive Vice President, Finance and Chief Financial Officer starting on or about March 31, 2025
On October 9, 2024, M-tron Industries, Inc. ("MtronPTI" or the "Company") announced the appointment of Cameron Pforr to serve as Chief Financial Officer, effective October 3, 2024.
The Board also appointed Joseph A. Riccelli to serve as the registrant’s Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer, effective immediately.
Departed
Joseph Riccelli, Sr.
Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer
the Board accepted the resignation of Joseph Riccelli, Sr. as the registrant’s Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer, effective immediately.
Appointed
Jatinder Dhaliwal
Chief Executive Officer
Virpax Pharmaceuticals, Inc.
Effective
2024-10-06
Filed
October 9, 2024, 7:59 PM ET
On October 6, 2024, the Board appointed Jatinder Dhaliwal, a member of the Board, to serve as Chief Executive Officer of the Company, effective immediately.
Departed
Gerald Bruce
Chief Executive Officer
Virpax Pharmaceuticals, Inc.
Effective
2024-10-05
Successor
Jatinder Dhaliwal
Filed
October 9, 2024, 7:59 PM ET
On October 5, 2024, Gerald Bruce, as Chief Executive Officer and member of the Board of Directors (the “Board”), and Vinay Shah, as Chief Financial Officer, notified the Company of their resignation from their respective positions, effective immediately.
Departed
Vinay Shah
Chief Financial Officer
Virpax Pharmaceuticals, Inc.
Effective
2024-10-05
Filed
October 9, 2024, 7:59 PM ET
On October 5, 2024, Gerald Bruce, as Chief Executive Officer and member of the Board of Directors (the “Board”), and Vinay Shah, as Chief Financial Officer, notified the Company of their resignation from their respective positions, effective immediately.
Departed
R. Lee Phegley, Jr.
Chief Financial Officer
Invesco Commercial Real Estate Finance Trust, Inc.
Successor
Courtney Popelka
Filed
October 9, 2024, 7:59 PM ET
On October 2, 2024, R. Lee Phegley, Jr., Chief Financial Officer of Invesco Commercial Real Estate Finance Trust, Inc. (the "Company") notified the Company of his intention to resign from the Company to pursue other opportunities.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.